The goal of pharmacovigilance activities is to ensure the safe use of medicines throughout their life cycle. Pharmacovigilance activities are carried out by several stakeholders, such as the European Medicines Agency (EMA), the national competent authorities of the EU member states, the European Commission, and the World Health Organization (WHO). Pharmaceutical companies are also strongly involved in pharmacovigilance and in promoting patient safety.

In the Nordic countries, there are several pharmacovigilance obligations that pharmaceutical companies must consider when their medicines are introduced to the market. Oriola's pharmacovigilance experts, who help pharmaceutical companies deal with their pharmacovigilance obligations in the Nordics, have compiled a handy information package on common local obligations that pharmaceutical companies face in this area.

Would you like to upload the information package?

Fill in your contact details below to get insight of pharmacovigilance from Oriola.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Oriola Oyj published this content on 09 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 December 2021 12:41:03 UTC.